The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.
Maria Vassilakopoulou
No relevant relationships to disclose
Jennifer Bordeaux
No relevant relationships to disclose
Veronique Neumeister
No relevant relationships to disclose
Huan Cheng
No relevant relationships to disclose
Kurt Schalper
No relevant relationships to disclose
Dimosthenis V. Skarlos
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
Nicholas Pavlidis
No relevant relationships to disclose
Angelos Koutras
No relevant relationships to disclose
Helena Linardou
No relevant relationships to disclose
Evangelia Razis
No relevant relationships to disclose
Mattheos Bobos
No relevant relationships to disclose
Vassiliki Kotoula
No relevant relationships to disclose
David Rimm
Consultant or Advisory Role - HistoRX
Stock Ownership - HistoRX
George Fountzilas
No relevant relationships to disclose
Amanda Psyrri
No relevant relationships to disclose